First patient dosed in Phase I trial of IPH4102
Innate Pharma receives development milestone payment from Bristol-Myers Squibb
Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
First patient treated in phase I/II trial with IPH2201 in ovarian cancer
Presentation of IPH4102 rationale and phase I design at the cutaneous lymphoma task force meeting of the EORTC
Fifth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification
Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC cutaneous lymphoma task force meeting
IPC, the comprehensive cancer center of Marseille, and Innate Pharma collaborate on translational research for novel immune checkpoint inhibitors
Innate Pharma and AstraZeneca announce global co-development and commercialisation agreement for IPH2201 in immuno-oncology
Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate’s site-specific conjugation technology
